Venor Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-06-2024
- Paid Up Capital ₹ 1.00 M
as on 17-06-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 42.98 Cr
as on 17-06-2024
- Revenue 18.74%
(FY 2023)
- Profit 66.15%
(FY 2023)
- Ebitda 47.05%
(FY 2023)
- Net Worth 125.03%
(FY 2023)
- Total Assets 45.85%
(FY 2023)
About Venor Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹42.98 Cr.
Shivam Verma, Yogesh Kapoor, Shubham Verma, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74900DL2013PLC251565
- Company No.
251565
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Venor Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivam Verma  | Director | 24-May-2023 | Current |
| Yogesh Kapoor | Director | 08-Feb-2023 | Current |
| Shubham Verma | Director | 31-Aug-2018 | Current |
| Savita Verma | Director | 03-May-2013 | Current |
| Vishwas Verma | Director | 03-May-2013 | Current |
Financial Performance of Venor Pharma.
Venor Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.74% increase. The company also saw a substantial improvement in profitability, with a 66.15% increase in profit. The company's net worth Soared by an impressive increase of 125.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venor Pharma?
In 2023, Venor Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Verve Health Care LimitedActive 21 years 2 monthsShubham Verma, Savita Verma and 1 more are mutual person
- Saisha Homes Private LimitedActive 5 years 6 months
Shubham Verma and Savita Verma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 May 2023 | ₹15.00 Cr | Open |
Hdfc Bank Limited Creation Date: 20 Dec 2022 | ₹15.00 Cr | Open |
Others Creation Date: 02 Aug 2022 | ₹12.98 Cr | Open |
How Many Employees Work at Venor Pharma?
Venor Pharma has a workforce of 170 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venor Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venor Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
